Trial Profile
Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Antihyperglycaemics; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 12 Jul 2023 Planned End Date changed from 28 Feb 2025 to 31 Dec 2024.
- 12 Jul 2023 Planned primary completion date changed from 1 Sep 2024 to 31 Dec 2024.
- 09 Apr 2021 Planned number of patients changed from 99999 to 1125000.